The expression of CB1 and CB2 depends on the cell and tissue types. CB1 is expressed in the brain 3) while CB2 is almost exclusively expressed on cells in the immune system. 4, 7) In the immune system, CB2 is known to be expressed on Blymphocytes, natural killer (NK) cells, eosinophils, and macrophages, and slightly on CD4 ϩ and CD8 ϩ lymphocytes. [8] [9] [10] CB2 mRNA is detected at the highest level in B-lymphocytes, but is also found in NK cells, monocytes, neutrophils, and CD8 ϩ and CD4 ϩ T-lymphocytes. 7) One of the functions attributed to cannabinoids in the immune system is the modulation of leukocyte migration. For example, 2-AG, an endocannabinoid, acts as a chemoattractant for macrophage-like cells, 11) human peripheral blood eosinophils, 10) NK cells, 12) dendritic cells, 13) and mouse lymphocytes. 14, 15) As for lymphocytes, 2-AG preferentially induces the migration of resting B-lymphocytes, but not that of T-lymphocytes from mouse spleen via the CB2 receptor. 15) We speculated that cannabinoids might modulate the migration of B cells induced by certain chemokines. Chemokines have been shown to regulate leukocyte trafficking to sites of inflammation. 16) Chemokines also participate in a variety of physiological and pathological processes. 17, 18) Several chemokines are known to trigger biological responses of B cells. [19] [20] [21] [22] CXCL12, also called stromal cellderived factor 1 (SDF-1), causes a chemotactic response of progenitor B cells in bone marrow. [23] [24] [25] CXCL12 binds to CXCR4 (a Gai-coupled GPCR), which is widely expressed on leukocytes including B-lymphocytes.
In this study, we investigated the effects of cannabinoids on lymphocyte migration toward CXCL12. As expected, WIN55,212-2 induced lymphocyte migration. On the other hand, this cannabinoid receptor agonist inhibited B cell migration toward CXCL12 at a high dose, suggesting the modulatory role of cannabinoids in B cell migration.
MATERIALS AND METHODS
Mice Specific pathogen-free female BALB/c mice were purchased from Japan SLC Inc. (Shizuoka, Japan) and used at 6 weeks of age. Animal care and experiments were performed in accordance with the guidelines for the care and use of laboratory animals of the University of Shizuoka.
Reagents WIN55,212-2 was purchased from Cayman Chemical Co. (Ann Arbor, MI, U.S.A.), recombinant mouse CXCL12 from R and D Systems (Minneapolis, MN, U.S.A.), RPMI1640 from Nissui Pharmaceuticals (Tokyo, Japan), bovine serum albumin (BSA) of fatty acid free/low-endotoxin grade and BSA fraction V from Sigma (St. Louis, MO, U.S.A.), kanamycin sulfate and dimethylsulfoxide (DMSO) from Wako Pure Chemicals (Osaka, Japan), N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES) from Nacalai Tesque (Kyoto, Japan), Lympholyte-M from Cedarlane (Ontario, Canada), and B cell isolation kit for mouse from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany).
Cell Migration Assays BALB/c mice were killed by cervical dislocation. Spleen cells were released by gentle teasing with needles in RPMI 1640 and then passed through a stainless steel screen. Splenic lymphocytes were purified by density gradient centrifugation with Lympholyte-M. Migration assays were performed using transwell inserts (for 24-well plates) of 6.5 mm diameter with 5-mm pore size membrane (Corning Costar, Amsterdam, Netherlands). For migration assays, 1ϫ10 6 lymphocytes suspended in 100 ml of RPMI 1640 medium containing 0.1% BSA (fatty acid-free) were added to the top well of each transwell insert. In the bottom chamber, 600 ml of RPMI 1640 medium containing 0.1% BSA was added. Samples were added to the bottom chambers, or the both the top wells and bottom chambers. After 4 h incubation at 37°C under 5% CO 2 /95% air, the numbers of cells recovered from the bottom chambers were determined.
Isolation of B Cells
Purified B cells (Ͼ95% purity) were obtained from mouse splenic lymphocytes by negative selection using B cell isolation kit for mouse.
Statistical Analyses Analysis of variance (ANOVA) followed by Dunnett's test was performed for multiple comparisons.
RESULTS

Chemotaxis of Splenic Lymphocytes toward a Synthetic Cannabinoid Receptor Agonist
Cannabinoid receptor agonists have been reported to induce the migration of different types of cells. [10] [11] [12] [13] [14] [15] We previously observed that splenic lymphocytes migrate toward 2-AG, an endocannabinoid. We examined whether or not splenic lymphocytes migrate toward WIN55,212-2, a synthetic cannabinoid receptor agonist, during 4 h-incubation. WIN55,212-2 was added to the bottom chambers at 0.001, 0.1, and 10 mM and splenic lymphocytes were added to the top well. Within the concentration range of 0.001 to 0.1 mM, WIN55,212-2 increased lymphocyte migration. A higher concentration of WIN55,212-2 (10 mM) did not enhance the migration (Fig.  1 ). We examined whether or not the lack of enhanced migration with the high concentration was due to the cytotoxicity of WIN55,212-2. After splenic lymphocytes had been incubated with or without 10 mM WIN55,212-2 for 4 h at 37°C, cell viability was determined to be 96.9Ϯ0.70% (with WIN55,212-2) and 96.0Ϯ0.80% (without WIN55,212-2) by means of the trypan blue dye exclusion test (meanϮS.D.). Thus, the lack of chemotactic activity with 10 mM WIN55,212-2 was not due to its cytotoxicity.
A Cannabinoid Receptor Agonist Inhibits CXCL12-Induced Chemotaxis of Lymphocytes The lack of chemotactic activity of WIN55,212-2 at a high concentration suggested a possible inhibitory effect on chemotaxis through cannabinoid receptor ligation. We examined the effect of WIN55,212-2 on CXCL12-induced chemotaxis. Lymphocyte migration was observed when CXCL12 was present in the bottom chamber. When 10 mM WIN55,212-2 was added to both the top well and the bottom chamber, CXCL12-induced chemotaxis was significantly inhibited (Fig. 2A) . We then examined the effect of pre-treatment of lymphocytes with WIN55,212-2. Lymphocytes were pre-treated with 10 mM WIN55,212-2 for 1 h and then the cells were washed to remove WIN55,212-2. When the cells were immediately subjected to the chemotaxis assay as to CXCL12, WIN55,212-2 still exhibited an inhibitory effect (Fig. 2B) . However, such an inhibitory effect of WIN55,212-2 was completely abolished after the lymphocytes had been cultured for 6 h before the chemotaxis assay (Fig. 2C) . Thus, a reversible inhibitory effect of WIN55,212-2 on lymphocyte chemotoxis was demonstrated.
Inhibition of CXCL12-Induced Chemotaxis of B-Lymphocytes by a Cannabinoid Receptor Agaonist We previously demonstrated that B-lymphocytes were selectively attracted by 2-AG. 15 ) Thus, we examined whether or not WIN55,212-2 affected CXCL12-induced chemotaxis of purified splenic B-lymphocytes. B-Lymphocyte migration toward CXCL12 was inhibited in the presence of 10 mM WIN55,212-2 ( Fig. 3) . 
DISCUSSION
Cannabinoids exhibit immuneregulatory functions via cannabinoid receptors. The cannabinoid receptors belong to a family of seven-transmembrane GPCR. Several GPCR, such as sphingosine-1-phosphate (S1P) receptors, are known to be important for cell migration, maturation, and proliferation. 26) Among the cannabinoid receptors, CB2 is expressed predominantly on immune cells. The involvement of CB2 in acute inflammation has been demonstrated in a mouse model. 27) In addition, the administration of THC has been shown to inhibit disease progression through the reduction of infiltration of CB2 positive macrophages. 28) Another study also demonstrated the anti-inflammatory activity of cannabinoids in mice. 29) Several studies have shown that 2-AG, which is an endocannabinoid, induces the migration of various types of cells. [10] [11] [12] [13] [14] [15] It has also been reported that 2-AG induced actin polymerization in HL-60 cells that had differentiated into macrophage-like cells. 30) However, many aspects of the cellular and molecular mechanisms underlying immunoregulaton remain to be elucidated.
We previously demonstrated that 2-AG induced the migration of mouse splenic lymphocytes via CB2 with selectivity for B cells, especially unstimulated ones. 15) In the present study, we observed that WIN55,212-2, a synthetic cannabinoid receptor agonist, induced splenic lymphocyte migration. WIN55,212-2 induced lymphocyte migration in the range of 0.001-0.1 mM. An optimal concentration range for inducuction of lymphocyte migration was observed because no migration was observed at 10 mM. We excluded the possibility that WIN55,212-2 affected cell migration because of a reduction in cell viability at high concentration. Other studies have also indicated WIN55,212-2 does not exhibit cytotoxicity. [31] [32] [33] The presence of such an optimal concentration has been demonstrated for S1P, which induces chemotaxis of CD4 ϩ cells, 34) as well as for lysophosphatidic acid (LPA), which inhibits chemokine-induced lymphocyte migration. 35) Therefore, the presence of an optimal concentration could be a common feature of cellular responses to lipid mediators.
A high dose of WIN55,212-2 not only failed to exhibit chemotactic activity toward lymphocytes, but also significantly inhibited CXCL12-induced chemotaxis of mouse splenic lymphocytes and purified B-lymphocytes. The inhibitory effect was transient and reversible. Considering that CXCL12 binds to CXCR4, one possibility is that the cannabinoid receptor and CXCR4 form dimers or oligomers in the presence of cannabinoids. This may alter the signaling through CXCR4. In fact, it has been demonstrated that CB1 not only forms homodimers, 36, 37) but also forms heterodimers with lysophosphatidic acid 1 receptors, 38) dopamine D2 receptors, 39) orexin 1 receptors, 40) and opioid receptors. 41) Homodimer formation by CB2 has also been demonstrated. 42) It has also been demonstrated that CXCR4 forms homo-and hetero-dimers. 43) It is not known whether or not CXCR4 forms heterodimers with CB1 or CB2. Heterodimer/oligomer formation may alter the downstream signaling of the receptors. 44) Alternatively, cannabinoid receptor ligation may cause heterologous desensitization of CXCR4. It has been demonstrated that the activation of receptors such as opioid receptors on the surface of leukocytes can inhibit chemokine receptor signaling through heterologous desensitization. 45) Because WIN55,212-2 is a non-selective cannabinoid receptor agonist, it is not clear whether the inhibitory effect on the chemokine-induced lymphocyte migration is mediated through CB1 or CB2. Weak expression of CB1 in mouse splenocytes has been demonstrated in mRNA level. 46) In contrast, we found that lymphocyte migration toward 2-AG was completely inhibited by SR144528, which is a CB2-selective antagonist. 15) This result suggests the majority of effects of endocannabinoid on lymphocyte migration are mediated through CB2. However, it would be interesting to determine whether the inhibitory effect of WIN55,212-2 on lymphocyte migration is also mediated through CB2.
The inhibitory effects of cannabinoids on CXCL12-induced chemotaxis are consistent with previous reports showing that cannabinoids inhibit CXCL12-induced T cell migration. 33, 47) However, the biological significance of these findings may not be important. That is, cannabinoid receptors in the immune system may be preferentially expressed in a B cell area like the marginal zone of the spleen, while their expression is low in the periarteriolar lymphatic sheaths (T cell area). 48) They are absent from T cell-enriched areas such as the thymus and the paracortex of the lymph nodes. 48) It is also known that CB2 mRNA expression in T-lymphocytes is low compared with in other immune cells. 7) Mice lacking the gene for CXCL12 or CXCR4 exhibit impaired B-cell lymphopoiesis. 49, 50) CXCL12 has a positioning effect by retaining B cell progenitors in appropriate niches in the bone marrow. 51) This positioning effect could be the result of chemotaxis of developing B lineage cells to their bone marrow location. Cannabinoid receptors may regulate the retention of B cells in the bone marrow by attenuating the response to CXCL12. Thus, CB2 ligation may facilitate the export of mature B cells from the bone marrow. Another possibility is that plasma cells may be attracted by CXCL12 without being inhibited by CB2 ligation, because activated B cells down regulate CB2. 15) This modulation may allow plasma cells to find an appropriate niche in the bone marrow to execute long-term synthesis of serum immunoglobulin G (IgG).
In conclusion, this study focused on the effects of cannabinoids on the chemotactic responses of splenic lymphocytes and B-lymphocytes toward CXCL12. A high dose of a cannabinoid inhibited B-lymphocyte chemotaxis toward CXCL12. Such activity may play a role in the immunomodulatory effects of cannabinoids.
